Global Heart Pump Device Market Size and Growth Trends and Forecast Report 2025-2033
Buy NowHeart Pump Device Market Size and Forecast 2025-2033
Heart Pump Device Market is expected to reach US$ 7.72 billion by 2033 from US$ 2.55 billion in 2024, with a CAGR of 13.1% from 2025 to 2033. Rising rates of cardiovascular diseases (CVDs), continuous technological development, an aging population in need of heart support, rising demand for minimally invasive (MI) procedures, and growing knowledge of heart failure treatment options are the main factors propelling the market.
Heart Pump Device Global Market Report by Product (Ventricular Assist Devices (VADs), Intra-aortic balloon pumps (IABPs), Extracorporeal Membrane Oxygenation (EMCO), Total Artificial Hearts (TAHs)), Type (Implanted Heart Pump Device, Extracorporeal Heart Pump Device), End Use (Hospitals, Cardiac Centers, Research Institutes), Countries and Company Analysis, 2025-2033.
Global Heart Pump Device Industry Overview
The growing prevalence of cardiovascular disorders and the growing need for cutting-edge treatment alternatives are driving the continuous rise of the worldwide heart pump device market. Patients with severe heart failure can benefit from these devices, which include intra-aortic balloon pumps, ventricular assist devices, and complete artificial hearts. Wider use throughout healthcare systems is being encouraged by advancements in minimally invasive technology and better patient outcomes. Improved healthcare infrastructure, more awareness, and growing applications in both short-term and long-term cardiac care are also helping the sector. The goal of ongoing research and development is to produce devices that are more patient-friendly, small, and effective in order to enhance quality of life.
About 620 million people worldwide, or roughly 1 in 13 people, suffer from heart and circulation disorders, according to current data from the British Heart Foundation (2024). Furthermore, according to the same report, in 2021, there were 340 million people in Asia and Australia and 100 million in Europe who suffered from cardiac and circulation disorders.
Additionally, according to current statistics from the British Heart Foundation (2024), an estimated 200 million individuals worldwide suffer from coronary (ischemic) heart disease, which is the most frequent diagnosis worldwide. Approximately 110 million males and 80 million women are impacted. Approximately 45 million men and 56 million women have also survived a stroke. Congenital cardiac disease is thought to affect at least 13 million individuals globally, and millions more may go untreated.
The data listed above demonstrate how urgently action is needed to reduce the growing global illness burden of CVDs. Conditions like arrhythmias and atherosclerosis can have an impact on a patient's quality of life. Furthermore, routine monitoring of heart rhythms and activities can often lessen the severity of CVDs. The use of heart pump devices can do this. These tools let patients and healthcare professionals identify conduction system deficiencies as needed, improving illness prognosis and facilitating early disease detection. As a result, throughout the projected period, the global market for heart pump devices is anticipated to develop significantly.
Key Factors Driving the Heart Pump Device Market Growth
Increasing Adoption of Mechanical Circulatory Assistance
One of the main factors propelling the worldwide market for heart pump devices is the increasing adoption of mechanical circulatory support, or MCS. MCS devices, including VADs, are becoming vital treatment choices for patients because to the rising incidence of heart failure and the scarcity of donor organs for transplantation. Of the adult patients listed for heart transplants between 2016 and 2018, 56.2% had gotten their transplant at the end of the first year, 27.8% were in the waiting period, 5.0% had died, and 11.0% had had their transplant removed, according to the Scientific Registry of Transplant Recipients (SRTR). After three years, 19.2% had been removed, 7.8% were still waiting, 6.3% had passed away, and 66.7% had received a transplant. As a result, patients and healthcare professionals are depending more on MCS, which has the potential to extend longevity, enhance quality of life, and act as a stopgap measure until transplantation or destination therapy.
Destination therapy and the bridge to transplantation
The requirement for heart pump devices as palliative measures prior to transplant and destination therapy is a significant factor driving the global market for these devices. As a short-term or long-term solution, VADs are used to treat patients who are not eligible for or waiting for a heart transplant. With estimates indicating that over 6.5 million Americans over the age of 20 suffer from heart failure, there is an increasing need for effective bridge-to-transplant and destination treatment alternatives. Additionally, according to another study, 960,000 new instances of heart failure are recorded annually, which raises the demand for heart pump devices in these therapeutic settings.
Developments in Heart Pump Technology
The worldwide market for heart pump devices is expanding and innovating due to the upgrading of heart pump technology. More resilient, biocompatible, and efficient cardiac pump devices have been developed as a result of shrinking techniques, novel materials, and improved device functioning. For example, SynCardia is constantly developing new concepts for its complete artificial heart (TAH). They have been granted a new patent for their next-generation TAH designs for patients waiting for a heart transplant who have end-stage biventricular failure. Furthermore, the integration of contemporary monitoring technologies and data analytics has enabled the customization of remote monitoring and patient management, enhancing overall patient safety and care. The market for these life-saving devices is growing as a consequence of ongoing research and development into heart pump technology.
Challenges in the Heart Pump Device Market
Availability of Expensive Devices
In patients with serious cardiac problems, heart pump devices are one of the most cutting-edge medical technologies utilized to support or replace heart function. However, the expensive cost of these devices and the procedures required to implant them is one of the main issues the sector is now experiencing. Strict production standards, sophisticated engineering, and cutting-edge materials are all necessary for these gadgets, which raises their cost. The total cost is further increased by the surgical process, after care, and ongoing maintenance. As a result, many patients cannot afford such care, especially in areas with low and intermediate incomes. For economically disadvantaged communities, access to life-saving care is further limited by limited insurance coverage and, in certain countries, a lack of government support.
Complex Surgical Procedures
Another major obstacle in the market is the need for complicated surgical procedures for the insertion of heart pump devices, such as ventricular assist devices (VADs). A group of highly qualified cardiac surgeons, state-of-the-art medical facilities, and specialized postoperative care are required for these extremely complex procedures. Unfortunately, there aren't many of these tools available, especially in rural or underdeveloped healthcare settings. Patient safety may be at risk due to problems like infections or mechanical failure brought on by inexperienced handling or inadequate follow-up treatment. Additionally, the adoption of the newest heart pump technologies may be slowed by the learning curve for surgeons and medical teams to become adept with them. Because of this, even at institutions with ample resources, the intricacy of the procedures may prevent these life-saving therapies from being widely used and accessible.
Heart Pump Device Market Overview by Regions
Because of its high prevalence of heart failure and sophisticated healthcare infrastructure, North America dominates the market for heart pump devices. Adoption and research support are considerable throughout Europe. Due to growing healthcare spending, awareness, and the rise in cardiovascular illnesses in developing nations, the Asia-Pacific area is developing quickly. The following provides a market overview by region:
United States Heart Pump Device Market
Due to a high prevalence of heart disease and robust healthcare infrastructure, the US heart pump device market is among the most developed and well-established in the world. Early adoption of cutting-edge medical technology, such as artificial hearts and next-generation ventricular support devices, helps the nation. Complex cardiac treatments are now more accessible because to the advanced surgical facilities and highly qualified staff found in major medical institutions and hospitals. Furthermore, robust R&D initiatives and encouraging reimbursement schemes encourage market expansion. Leading producers of medical devices are present, which also increases technical availability and innovation. The U.S. market continues to lead in the use and development of heart pump technology due to an aging population and rising awareness of sophisticated cardiac care.
Germany Heart Pump Device Market
Due to a strong healthcare system and a high prevalence of cardiovascular disorders, Germany leads the European market for heart pump devices. Advanced medical technology, highly qualified healthcare workers, and a focus on research and development are all advantageous to the nation. Innovative technologies like the EXCOR VAD, which helps patients with end-stage heart failure, are contributed to the market by major manufacturers like Berlin Heart. Germany is a key center for the development and use of heart pump devices in Europe because of its dedication to both technical innovation and high-quality healthcare.
According to the Deutscher Herzbericht 2022, coronary heart disease (CHD) was responsible for 121,172 fatalities in 2021, including 45,181 from acute heart attacks, making it the country's biggest cause of death.
China Heart Pump Device Market
The rising incidence of cardiovascular disorders and improvements in medical technology are fueling the market for heart pump devices in China, which is expanding quickly. Ventricular assist devices (VADs) and other heart pump technologies are becoming more and more popular throughout the nation as therapy alternatives for people suffering from severe heart failure. Government programs to enhance healthcare infrastructure and provide access to cutting-edge medical treatments are helping to sustain this growth. Collaborations between foreign medical device businesses and indigenous producers are also helping the industry by improving product offers and enabling localized production. China is thus becoming a major force in the worldwide market for heart pump devices, and more expansion is projected in the upcoming years.
According to the Annual Report on Cardiovascular Health and Diseases in China (2021), 8.9 million Chinese individuals are thought to have heart failure. Furthermore, Yongrenxin Medical Instrument Co. Ltd. obtained around USD 100 million in series A investment in March 2023 to create a platform for the treatment of heart failures.
Saudi Arabia Heart Pump Device Market
The market for heart pump devices in Saudi Arabia is expanding significantly due to the rising incidence of cardiovascular conditions and developments in medical technology. Ventricular assist devices (VADs) and other heart pump technologies are becoming more and more popular throughout the nation as therapy alternatives for people suffering from severe heart failure. Government programs to enhance healthcare infrastructure and provide access to cutting-edge medical treatments are helping to sustain this growth. Collaborations between foreign medical device businesses and indigenous producers are also helping the industry by improving product offers and enabling localized production. Saudi Arabia is thus becoming a major force in the worldwide market for heart pump devices, and more expansion is projected in the upcoming years.
Market Segmentations
Product
- Ventricular Assist Devices (VADs)
- Intra-aortic balloon pumps (IABPs)
- Extracorporeal Membrane Oxygenation (EMCO)
- Total Artificial Hearts (TAHs)
Type
- Implanted Heart Pump Device
- Extracorporeal Heart Pump Device
End Use
- Hospitals
- Cardiac Centers
- Research Institutes
Regional Outlook
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
All the Key players have been covered
- Overview
- Key Persons
- Recent Development & Strategies
- Revenue Analysis
Company Analysis:
- Abbott Inc.
- Getinge AB.
- Teleflex Incorporated
- Fresenius SE & Co. KGaA
- LivaNova PLC
- CorWave SA
- JARVIK HEART, INC.
- ABIOMED
Report Details:
Report Features | Details |
Base Year |
2024 |
Historical Period |
2021- 2024 |
Forecast Period |
2025 - 2033 |
Market |
US$ Billion |
Segment Covered |
By Product, By Type, By End Use and By Countries |
Countries Covered |
|
Companies Covered |
|
Customization Scope |
20% Free Customization |
Post-Sale Analyst Support |
1 Year (52 Weeks) |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
2.1 Data Source
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Research Approach
2.2.1 Top-Down Approach
2.2.2 Bottom-Up Approach
2.3 Forecast Projection Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Heart Pump Device Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Heart Pump Device Market Share Analysis
6.1 By Product
6.2 By Type
6.3 By End Use
6.4 By Countries
7. Product
7.1 Ventricular Assist Devices (VADs)
7.2 Intra-aortic balloon pumps (IABPs)
7.3 Extracorporeal Membrane Oxygenation (EMCO)
7.4 Total Artificial Hearts (TAHs)
8. Type
8.1 Implanted Heart Pump Device
8.2 Extracorporeal Heart Pump Device
9. End Use
9.1 Hospitals
9.2 Cardiac Centers
9.3 Research Institutes
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa
11. Porter’s Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players Analysis
13.1 Abbott Inc.
13.1.1 Overview
13.1.2 Key Persons
13.1.3 Recent Development & Strategies
13.1.4 Revenue Analysis
13.2 Getinge AB.
13.2.1 Overview
13.2.2 Key Persons
13.2.3 Recent Development & Strategies
13.2.4 Revenue Analysis
13.3 Teleflex Incorporated
13.3.1 Overview
13.3.2 Key Persons
13.3.3 Recent Development & Strategies
13.3.4 Revenue Analysis
13.4 Fresenius SE & Co. KGaA
13.4.1 Overview
13.4.2 Key Persons
13.4.3 Recent Development & Strategies
13.4.4 Revenue Analysis
13.5 LivaNova PLC
13.5.1 Overview
13.5.2 Key Persons
13.5.3 Recent Development & Strategies
13.5.4 Revenue Analysis
13.6 CorWave SA
13.6.1 Overview
13.6.2 Key Persons
13.6.3 Recent Development & Strategies
13.6.4 Revenue Analysis
13.7 JARVIK HEART, INC.
13.7.1 Overview
13.7.2 Key Persons
13.7.3 Recent Development & Strategies
13.7.4 Revenue Analysis
13.8 ABIOMED
13.8.1 Overview
13.8.2 Key Persons
13.8.3 Recent Development & Strategies
13.8.4 Revenue Analysis
Reach out to us
Call us on
USA: +1-478-202-3244
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com